Literature DB >> 16041447

[Annual cost of ischemic heart disease in Brazil. Public and private perspective].

Rodrigo A Ribeiro1, Renato G B Mello, Raquel Melchior, Juliana C Dill, Clarissa B Hohmann, Angélica M Lucchese, Ricardo Stein, Jorge Pinto Ribeiro, Carisi A Polanczyk.   

Abstract

OBJECTIVE: To estimate the annual cost of coronary artery disease (CAD) management in Public Health Care System (SUS) and HMOs values in Brazil.
METHODS: Cohort study, including ambulatory patients with proven CAD. Clinic visits, exams, procedures, hospitalizations and medications were considered to estimate direct costs. Values of appointments and exams were obtained from the SUS and the Medical Procedure List (LPM 1999) reimbursement tables. Costs of cardiovascular events were obtained from admissions in public and private hospitals with similar diagnoses-related group classifications in 2002. The price of medications used was the lowest found in the market.
RESULTS: The 147 patients (65 +/- 12 years old, 63% men, 69% hypertensive, 35% diabetic and 59% with previous AMI) had an average follow-up of 24 +/- 8 months. The average estimated annual cost per patient was R$ 2,733.00, for the public sector, and R$ 6,788.00, for private and fee-for-service plans. Expenses with medications (R$ 1,154.00) represented 80% and 55% of outpatient costs, and 41% and 17% of total expenses, in public and non-public sectors, respectively. The occurrence of cardiovascular event had a great impact (R$ 4,626.00 vs. R$ 1,312.00, in SUS, and R$ 13,453.00 vs. R$ 1,789.00, for HMOs, p<0.01) on the results.
CONCLUSION: The average annual cost of CAD management was high, being the pharmacological treatment the main determinant of public costs. Such estimates may subsidize economical analyses in this area, and foster related healthcare policies.

Entities:  

Mesh:

Year:  2005        PMID: 16041447     DOI: 10.1590/s0066-782x2005001400002

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  9 in total

1.  Direct medical cost of newly diagnosed stable coronary artery disease in Hong Kong.

Authors:  Vivian W Y Lee; Yat Yin Lam; Amy C M Yuen; Shuk Yan Cheung; Cheuk-Man Yu; Bryan P Y Yan
Journal:  Heart Asia       Date:  2013-01-02

2.  Long-term Cost-Effectiveness of Diagnostic Tests for Assessing Stable Chest Pain: Modeled Analysis of Anatomical and Functional Strategies.

Authors:  Eduardo G Bertoldi; Steffan F Stella; Luis E Rohde; Carisi A Polanczyk
Journal:  Clin Cardiol       Date:  2016-04-15       Impact factor: 2.882

Review 3.  A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.

Authors:  Ching-Yun Wei; Ruben G W Quek; Guillermo Villa; Shravanthi R Gandra; Carol A Forbes; Steve Ryder; Nigel Armstrong; Sohan Deshpande; Steven Duffy; Jos Kleijnen; Peter Lindgren
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

4.  Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.

Authors:  Rodrigo Antonini Ribeiro; Bruce Bartholow Duncan; Patricia Klarmann Ziegelmann; Steffan Frosi Stella; Jose Luiz da Costa Vieira; Luciane Maria Fabian Restelatto; Carisi Anne Polanczyk
Journal:  Arq Bras Cardiol       Date:  2014-11-18       Impact factor: 2.000

Review 5.  Tai Chi Chuan for cardiac rehabilitation in patients with coronary arterial disease.

Authors:  Rosane Maria Nery; Maurice Zanini; Juliana Nery Ferrari; César Augusto Silva; Leonardo Fontanive Farias; João Carlos Comel; Karlyse Claudino Belli; Anderson Donelli da Silveira; Antonio Cardoso Santos; Ricardo Stein
Journal:  Arq Bras Cardiol       Date:  2014-04-17       Impact factor: 2.000

6.  Estimation and determinants of direct medical costs of ischaemic heart disease, stroke and hypertensive heart disease: evidence from two major hospitals in Cameroon.

Authors:  Leopold Ndemnge Aminde; Anastase Dzudie; Yacouba N Mapoure; Jacques Cabral Tantchou; J Lennert Veerman
Journal:  BMC Health Serv Res       Date:  2021-02-12       Impact factor: 2.655

7.  Estimating the direct costs of ischemic heart disease: evidence from a teaching hospital in BRAZIL, a retrospective cohort study.

Authors:  Rosane Paixão Schlatter; Vânia Naomi Hirakata; Carisi Anne Polanczyk
Journal:  BMC Cardiovasc Disord       Date:  2017-07-04       Impact factor: 2.298

8.  Estimated cost of asthma in outpatient treatment: a real-world study.

Authors:  Eduardo Costa; Rosangela Caetano; Guilherme Loureiro Werneck; Maurício Bregman; Denizar Vianna Araújo; Rogério Rufino
Journal:  Rev Saude Publica       Date:  2018-04-09       Impact factor: 2.106

9.  Cost-Effectiveness of Rheumatic Heart Disease Echocardiographic Screening in Brazil: Data from the PROVAR+ Study: Cost-effectiveness of RHD screening in Brazil.

Authors:  Jasper Ubels; Craig Sable; Andrea Z Beaton; Maria Carmo P Nunes; Kaciane K B Oliveira; Lara C Rabelo; Isabella M Teixeira; Gabriela Z L Ruiz; Letícia Maria M Rabelo; Alison R Tompsett; Antonio Luiz P Ribeiro; Klas-Göran Sahlen; Bruno R Nascimento
Journal:  Glob Heart       Date:  2020-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.